Insmed INSM INS1148 — R&D

Other product segments

Similar metrics at other companies

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

NRIXInternal research and development expenses — R&D

$56.56M+1.6%

GERNResearch and clinical expenses — R&D

$13M-5.1%

SLDBInternal Research And Development Expense — Research And Development Expense

$9.15M+33.7%

NRIXNX-1607 — R&D

$1.74M-25.5%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

Questions, answered.

What is Insmed's INS1148 — R&D?

Insmed (INSM) reported INS1148 — R&D of $10M in Q4 2025.

What does INS1148 — R&D mean?

This metric represents the direct operating expenses allocated to the research and development activities specifically associated with the INS1148 program. It captures the costs of clinical trials, preclinical studies, regulatory filings, and manufacturing process development required to advance this specific therapeutic candidate toward commercialization. Tracking this spend provides insight into the company's capital allocation strategy and the progression of its pipeline assets.